CSOP China Healthcare Disruption Index ETF (HKG:3174)
Hong Kong
· Delayed Price · Currency is HKD 2.590
-0.014 (-0.54%)
At close: May 28, 2025, 4:00 PM HKT
48.34% (1Y)
| Assets | 368.20M |
| Expense Ratio | 1.50% |
| PE Ratio | 18.47 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +47.31% |
| Volume | 252,700 |
| Open | 2.604 |
| Previous Close | 2.604 |
| Day's Range | 2.578 - 2.604 |
| 52-Week Low | 1.586 |
| 52-Week High | 2.800 |
| Beta | 0.48 |
| Holdings | 21 |
| Inception Date | Jul 21, 2021 |
About 3174
CSOP China Healthcare Disruption Index ETF is an exchange-traded fund directly investing in companies. It prefers to invest in companies based out of Hong Kong. It primarily invests the healthcare- pharmaceutical and medical device companies.
Asset Class Equity
Category Total Market
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3174
Provider CSOP
Index Tracked WISE Samsung Group Value Index- KRW - Benchmark Price Return
Performance
3174 had a total return of 47.31% in the past year, including dividends. Since the fund's inception, the average annual return has been -24.37%.
Top 10 Holdings
77.79% of assets| Name | Symbol | Weight |
|---|---|---|
| Hansoh Pharmaceutical Group Company Limited | 3692 | 9.87% |
| Innovent Biologics, Inc. | 1801 | 9.71% |
| CSPC Pharmaceutical Group Limited | 1093 | 9.06% |
| Akeso, Inc. | 9926 | 8.88% |
| Sino Biopharmaceutical Limited | 1177 | 8.35% |
| WuXi AppTec Co., Ltd. | 2359 | 8.16% |
| WuXi Biologics (Cayman) Inc. | 2269 | 7.60% |
| Alibaba Health Information Technology Limited | 0241 | 6.54% |
| Genscript Biotech Corporation | 1548 | 4.89% |
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | SFOSF | 4.72% |